Last reviewed · How we verify
Placebo to sitagliptin plus metformin
Placebo to sitagliptin plus metformin is a DPP-4 inhibitor and biguanide Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Placebo to MK-0431A, Placebo to MK-0431A XR.
Sitagliptin plus metformin works by inhibiting dipeptidyl peptidase-4 (DPP-4) and reducing glucose production in the liver, and increasing insulin secretion.
Sitagliptin plus metformin works by inhibiting dipeptidyl peptidase-4 (DPP-4) and reducing glucose production in the liver, and increasing insulin secretion. Used for Type 2 diabetes.
At a glance
| Generic name | Placebo to sitagliptin plus metformin |
|---|---|
| Also known as | Placebo to MK-0431A, Placebo to MK-0431A XR |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | DPP-4 inhibitor and biguanide |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, which in turn increases insulin release in response to meals and decreases glucose production in the liver. Metformin is a biguanide that decreases glucose production in the liver and increases insulin sensitivity.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
- Fatigue
Key clinical trials
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (PHASE3)
- A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes (PHASE3)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289) (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to sitagliptin plus metformin CI brief — competitive landscape report
- Placebo to sitagliptin plus metformin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to sitagliptin plus metformin
What is Placebo to sitagliptin plus metformin?
How does Placebo to sitagliptin plus metformin work?
What is Placebo to sitagliptin plus metformin used for?
Who makes Placebo to sitagliptin plus metformin?
Is Placebo to sitagliptin plus metformin also known as anything else?
What drug class is Placebo to sitagliptin plus metformin in?
What development phase is Placebo to sitagliptin plus metformin in?
What are the side effects of Placebo to sitagliptin plus metformin?
What does Placebo to sitagliptin plus metformin target?
Related
- Drug class: All DPP-4 inhibitor and biguanide drugs
- Target: All drugs targeting DPP-4
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: Placebo to MK-0431A, Placebo to MK-0431A XR
- Compare: Placebo to sitagliptin plus metformin vs similar drugs
- Pricing: Placebo to sitagliptin plus metformin cost, discount & access